A Study to Assess Safety, Tolerability and Pharmacokinetics of GLPG2737 in Healthy Subjects

NCT03410979 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

79

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: GLPG2737 single dose
DRUG: Placebo single dose
DRUG: GLPG2737 multiple dose
DRUG: GLPG2737 multiple dose

Sponsor

Lakefront Biotherapeutics NV